Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia


      A novel animal model of insulin resistance, the fructose-fed Syrian golden hamster, was employed to investigate the efficacy and mechanisms of action of rosuvastatin, a HMG-CoA reductase inhibitor, in ameliorating metabolic dyslipidemia in insulin-resistant states. Fructose feeding for a 2-week period induced insulin resistance and a significant increase in hepatic secretion of VLDL. This was followed by a fructose-enriched diet with or without 10 mg/kg rosuvastatin for 14 days. Fructose feeding in the first 2 weeks caused a significant increase in plasma total cholesterol and triglyceride in both groups (n = 6, p < 0.001). However, there was a significant decline (30%, n = 8, p < 0.05) in plasma triglyceride levels following rosuvastatin feeding (10 mg/kg). A significant decrease (n = 6, p < 0.05) was also observed in VLDL-apoB production in hepatocytes isolated from drug-treated hamsters, together with an increased apoB degradation (n = 6, p < 0.05). Similar results were obtained in parallel cell culture experiments in which primary hepatocytes were first isolated from chow-fed hamsters, and then treated in vitro with 15 μM rosuvastatin for 18 h. Rosuvastatin at 5 μM caused a substantial reduction in synthesis of unesterified cholesterol and cholesterol ester (98 and 25%, n = 9, p < 0.01 or p < 0.05) and secretion of newly synthesized unesterified cholesterol, cholesterol ester, and triglyceride (95, 42, and 60% reduction, respectively, n = 9, p < 0.01 or p < 0.05). This concentration of rosuvastatin also caused a significant reduction (75% decrease, n = 4, p < 0.01) in the extracellular secretion of VLDL-apoB100, accompanied by a significant increase in the intracellular degradation of apoB100. There was a 12% reduction (not significant, p > 0.05) in hepatic MTP and no changes in ER-60 (a chaperone involved in apoB degradation) protein levels. Taken together, these data suggest that the assembly and secretion of VLDL particles in hamster hepatocytes can be acutely inhibited by rosuvastatin in a process involving enhanced apoB degradation. This appears to lead to a significant amelioration of hepatic VLDL-apoB overproduction observed in the fructose-fed, insulin-resistant hamster model.


      apoB (apolipoprotein B), ER (endoplasmic reticulum), FF (fructose-fed), HDL (high density lipoproteins), LDL (low density lipoproteins), MEM (minimum essential medium), MTP (microsomal triglyceride transfer protein), PAGE (polyacrylamide gel electrophoresis), PMSF (phenylmethylsulfonylfluoride), SDS (sodium dodecyl sulfate), SREBP (sterol regulatory element binding protein), VLDL (very low-density lipoproteins)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reaven G.M.
        The role of insulin resistance and hyperinsulinemia in coronary heart disease.
        Metabolism. 1992; 41: 16
        • Lewis G.F.
        • Steiner G.
        Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state.
        Diab Care. 1996; 19: 390
        • Lewis G.F.
        • Carpentier A.
        • Adeli K.
        • Giacca A.
        Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
        Endocr Rev. 2002; 23: 201-229
        • Grundy S.M.
        • Mok H.Y.
        • Zech L.
        • Steinberg D.
        • Berman M.
        Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia.
        J Clin Invest. 1979; 63: 1274
        • Kissebah A.H.
        • Alfarsi S.
        • Adams P.W.
        Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.
        Metabolism. 1981; 30: 856
        • Reaven G.M.
        Banting lecture 1988. Role of insulin resistance in human disease.
        Diabetes. 1988; 37: 1595
        • Lakka H.M.
        • Laaksonen D.E.
        • Lakka T.A.
        • et al.
        The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
        JAMA. 2002; 288: 2709-2716
        • Avramoglu R.K.
        • Qiu W.
        • Adeli K.
        Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion.
        Front Biosci. 2003; 8: D464-D476
        • Mykkanen L.
        • Haffner S.M.
        • Ronnemaa T.
        • et al.
        Is there a sex difference in the association of plasma insulin level and insulin sensitivity with serum lipids and lipoproteins?.
        Metabolism. 1994; 43: 523
        • Garg A.
        • Helderman J.H.
        • Koffler M.
        • et al.
        Relationship between lipoprotein levels and in vivo insulin action in normal young white men.
        Metabolism. 1988; 37: 982
      1. Expert Panel Report on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486–97.

        • Olsson A.G.
        • Pears J.
        • McKellar J.
        • Mizan J.
        • Raza A.
        Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
        Am J Cardiol. 2001; 88: 504-508
        • Blasetto J.W.
        • Stein E.A.
        • Brown W.V.
        • Chitra R.
        • Raza A.
        Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special populations groups.
        Am J Cardiol. 2003; 91: 3C-10C
        • Ballantyne C.M.
        • Stein E.A.
        • Paoletti R.
        • Southworth H.
        • Blasetto J.W.
        Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
        Am J Cardiol. 2003; 91: 25C-28C
        • Hunninghake D.B.
        • Stein E.A.
        • Bays H.E.
        • et al.
        Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.
        Coron Artery Dis. 2004; 15: 115-123
        • Adeli K.
        • Taghibiglou C.
        • Carpentier A.
        • Lewis G.F.
        Mechanisms of hepatic very low-density lipoprotein overproduction of VLDL in insulin resistance.
        Trends Cardiovasc Med. 2001; 11: 170-176
        • Taghibiglou C.
        • Rashid-Kolvear F.
        • Van Iderstine B.
        • et al.
        Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
        J Biol Chem. 2002; 277: 793-803
        • Carpentier A.
        • Taghibiglou C.
        • Leung N.
        • et al.
        Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster.
        J Biol Chem. 2002; 277: 28795-28802
        • Haidari M.
        • Leung N.
        • Mahbub F.
        • et al.
        Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and apoB48-containing lipoprotein overproduction.
        J Biol Chem. 2002; 277: 31646-31655
        • Taghibiglou C.
        • Rudy D.
        • Aiton A.
        • Adeli K.
        Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes.
        J Lipid Res. 2000; 41: 499-513
        • Taghibiglou C.
        • Carpentier A.
        • Van Iderstine S.C.
        • et al.
        Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model.
        J Biol Chem. 2000; 275: 8416-8425
        • Istvan E.S.
        • Deisenhofer J.
        Structural mechanism for statin inhibition of HMG-CoA reductase.
        Science. 2001; 292: 1160-1164
        • Burnett J.R.
        • Wilcox L.J.
        • Telford D.E.
        • et al.
        The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
        Endocrinology. 1999; 140: 5293-5302
        • Huff M.W.
        • Burnett J.R.
        3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.
        Curr Opin Lipidol. 1997; 8: 138-145
        • Mohammadi A.
        • Macri J.
        • Newton R.
        • et al.
        Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
        Arterioscler Thromb Vasc Biol. 1998; 18: 783-793
        • Wilcox L.J.
        • Barrett P.H.
        • Huff M.W.
        Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
        J Lipid Res. 1999; 40: 1078-1089
        • Kasim-Karakas S.E.
        • Vriend H.
        • Almario R.
        • et al.
        Effects of dietary carbohydrates on glucose and lipid metabolism in golden Syrian hamsters.
        J Lab Clin Med. 1996; 128: 208-213
        • Ma P.T.
        • Gil G.
        • Sudhof T.C.
        • et al.
        Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.
        Proc Natl Acad Sci USA. 1986; 83: 8370-8374
        • Briggs M.R.
        • Yokoyama C.
        • Wang X.
        • et al.
        Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence.
        J Biol Chem. 1993; 268: 14490-14496
        • Qin W.
        • Infante J.
        • Wang S.R.
        • et al.
        Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
        Biochim Biophys Acta. 1992; 1127: 57-66
        • Tanaka M.
        • Jingami H.
        • Otani H.
        • et al.
        Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes.
        J Biol Chem. 1993; 268: 12713-12718
        • Mangaloglu L.
        • Taghibiglou C.
        • Chen B.
        • et al.
        Inhibition of HMG-CoA reductase ameliorates hepatic VLDL overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster.
        Metabolism. 2002; 5: 409-418
        • Sato R.
        • Miyamoto W.
        • Inoue J.
        • et al.
        Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription [in process citation].
        J Biol Chem. 1999; 274: 24714-24720
        • Vijan S.
        • Hayward R.A.
        • American College of Physicians
        Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.
        Ann Intern Med. 2004; 140: 650-658
        • Rosenson R.S.
        Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
        Expert Rev Cardiovasc Ther. 2003; 1: 495-505
        • Kendrach M.G.
        • Kelly-Freeman M.
        Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
        Ann Pharmacother. 2004; 38: 1286-1292
        • Shepherd J.
        • Hunninghake D.B.
        • Barter P.
        • McKenney J.M.
        • Hutchinson H.G.
        Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
        Atheroscler Suppl. 2003; 5: 115-123
        • Adeli K.
        • Macri J.
        • Mohammadi A.
        • Kito M.
        • Urade A.
        • Cavallo D.
        Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells.
        J Biol Chem. 1997; 272: 22489-22494
        • Qiu W.
        • Kohen-Avramoglu R.
        • Rashid-Kolvear F.
        • Au C.S.
        • Chong T.M.
        • Trinh D.
        • Adeli K.
        Adenoviral-mediated overexpression of ER-60 downregulates apolipoprotein B secretion: evidence for an ER-60 mediated degradative pathway responsible for post-translational and non-proteasomal apoB degradation.
        Biochemistry. 2004; 43: 4819-4831